MedX Health Corp. has announced a strategic partnership with Vitamed Biomedical and Medispa to expand the reach of its advanced teledermatology platform across Italy. This collaboration will see the deployment of MedX’s SIAscope on DermSecure® system throughout Medispa’s network of pharmacies, wellness centers, and medical facilities. By integrating into these high-traffic community locations, the partnership significantly increases public access to early skin cancer detection services, enabling patients to receive rapid, non-invasive dermatological assessments with specialist review—often within 72 hours.

At the core of this initiative is MedX’s innovative DermSecure® platform, a clinically validated solution that securely transmits high-resolution images of suspicious skin lesions for dermatologist evaluation. The technology has been approved for use in several key healthcare markets, including the EU, U.S., Canada, Australia, and the UK, and exemplifies the company’s mission to bring specialist-level dermatological care directly to communities. The Italian rollout marks another milestone in MedX’s global expansion strategy, reinforcing its commitment to delivering scalable, preventive health solutions through digital innovation.

This partnership also highlights the growing importance of collaboration and technology in modernizing healthcare delivery. By uniting MedX’s innovation with Vitamed’s distribution expertise and Medispa’s trusted healthcare presence, the initiative represents a powerful model for increasing access and promoting early intervention. With rising demand for dermatology services amid aging populations and heightened awareness of skin cancer risks, this initiative underscores the essential role of digital tools in driving timely diagnosis and better health outcomes on a global scale.

MedTech Spectrum's Summary

Innovative Technology: MedX’s SIAscope on DermSecure® platform enables rapid, non-invasive skin lesion imaging, providing secure, high-resolution images for dermatologist review—often within 72 hours—significantly accelerating diagnosis and reducing unnecessary referrals.

Global Expansion: With regulatory clearance across multiple regions including the EU, U.S., Canada, Australia, and the UK, this Italian partnership marks a strategic step in MedX’s international growth, bringing advanced teledermatology to new communities and healthcare settings.

Collaborative Impact: The partnership between MedX, Vitamed, and Medispa combines cutting-edge technology with trusted local healthcare networks, enhancing patient access to early skin cancer detection and demonstrating how innovation and collaboration can improve healthcare outcomes worldwide.